Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.48 |
| ▸ | IKBKB | O14920 | 6/20 | 0.45 |
| ▸ | CHUK | O15111 | 5/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | KMO | O15229 | 4/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 2/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337304 | 0.85 | KMO (0.41) | MAP2K1ROCK1KMO | |
| SCHEMBL2337307 | 0.85 | KMO (0.41) | MAP2K1ROCK1KMO | |
| Hydrochloric Acid SCHEMBL2338809 | 0.84 | KMO (0.41) | MAP2K1ROCK1KMO | |
| SCHEMBL4961099 | 0.84 | KMO (0.41) | MAP2K1ROCK1KMO | |
| SCHEMBL4608506 | 0.84 | KMO (0.41) | MAP2K1ROCK1KMO | |
| SCHEMBL4608510 | 0.84 | KMO (0.41) | MAP2K1ROCK1KMO | |
| Hydrochloric Acid SCHEMBL2338812 | 0.84 | KMO (0.41) | MAP2K1ROCK1KMO | |
| SCHEMBL4961096 | 0.84 | KMO (0.41) | MAP2K1ROCK1KMO | |
| SCHEMBL8934714 | 0.80 | HRH3 (0.39) | — | |
| SCHEMBL8939229 | 0.78 | IGF1R (0.39) | ROCK1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | MAP2K1 1916/4885ROCK1 8/4885IKBKB 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.